Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls. (NeuronsiPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03682458|
Recruitment Status : Not yet recruiting
First Posted : September 24, 2018
Last Update Posted : March 13, 2019
Neurological and neurodegenerative diseases have a major impact in families and in the national health service due to the lack in many cases of effective and long-lasting therapies. The lack of these therapeutic strategies is due in large part to the difficulty of modeling these pathologies in vitro. In fact, the impossibility of being able to cultivate human neurons in vitro has forced the use of animal cell models that do not adequately recapitulate the complexity of these human pathologies. For this reason it is necessary to proceed with the development of in vitro models of human origin that reproduce the molecular and biochemical characteristics of these diseases.
The discovery of cellular reprogramming allowed the generation of pluripotent stem cells from the conversion of somatic cells taken from adult individuals.
The proposing group already has great experience in generating iPS cells by reprogramming and in differentiating them into neurons and glias useful for neurological disease cellular studies. As an example, Dr. Broccoli's group has generated iPS cells from patients with Parkinson's disease and mutations in the OPA1 gene. The study of neurons differentiated by these iPS cells allowed to identify mitochondrial defects at the base of neuronal dysfunctions and to identify for the first time how the degeneration of dopaminergic neurons also depends on a moving mode of cell death called necroptosis.
The investigators therefore propose to establish lines of iPS cells from patients with genetic mutations responsible for neurological and neurodegenerative diseases to generate neuronal and glial models in vitro for the study of pathological mechanisms and the validation of new future experimental therapies.
|Condition or disease||Intervention/treatment|
|Neurodegenerative Diseases||Genetic: Study of Neurodegenerative Diseases Induced Stem Cells|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Study of Neurological Pathological Mechanisms of and Neurodegenerative Diseases in Neurons and Glia Derived From Induced Stem Cells (iPS) in Patients and Healthy Family Controls.|
|Estimated Study Start Date :||October 1, 2019|
|Estimated Primary Completion Date :||October 1, 2020|
|Estimated Study Completion Date :||October 1, 2022|
- Genetic: Study of Neurodegenerative Diseases Induced Stem Cells
The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
- Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls. [ Time Frame: 10 days ]1.Neurology consulting Clinical valuation
- Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls. [ Time Frame: 1 day ]2. Genetic Counseling family history
- Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls. [ Time Frame: 2 years ]
3. Molecular testing
- Molecular analysis
- iPS stem cells will be differentiated into neurons and glia for the study of the pathological mechanisms underlying neuropathology.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03682458
|Pozzilli, Isernia, Italy, 86077|